What side effects does Jakafi (ruxolitinib) cause?
Jakafi (ruxolitinib) commonly causes side effects tied to its effects on blood and immune signaling. Reported effects include anemia (low red blood cells) and thrombocytopenia (low platelets). Patients can also experience infections, including serious infections in some cases.[1][2]
Other side effects that may occur include bruising or bleeding (often related to low platelets), fatigue, dizziness, headache, and gastrointestinal symptoms such as nausea or diarrhea.[1][2]
How common are anemia and low platelets with Jakafi?
Anemia and thrombocytopenia are among the most monitored risks with Jakafi, because the drug can lower blood cell counts. Doctors typically check blood counts during treatment and may adjust the dose if counts drop.[1][2]
What serious side effects should patients watch for?
Serious side effects can include serious or opportunistic infections, since Jakafi affects immune signaling. Patients are generally advised to watch for signs of infection (such as fever or feeling very unwell) and seek medical care promptly.[1][2]
Jakafi can also be associated with other clinically significant events that require urgent attention when they occur (for example, severe bleeding related to low platelets).[1][2]
Does Jakafi cause changes in cholesterol, weight, or liver tests?
Jakafi can affect lab values during treatment, which may include changes in cholesterol and liver-related blood tests, depending on the patient and underlying disease. Clinicians monitor these labs and adjust management as needed.[1][2]
What infection risks come with Jakafi?
Because Jakafi works by altering cytokine/JAK signaling, it can increase susceptibility to infections. Reported infections range from common infections to serious infections, so clinicians typically assess infection history and monitor patients during therapy.[1][2]
Are side effects different in myelofibrosis vs polycythemia vera?
Jakafi is used for multiple diseases, including myelofibrosis and polycythemia vera, and the side-effect profile can vary by condition and baseline blood counts. In practice, anemia and low platelets remain key concerns across indications, but the overall frequency and severity of events can differ.[1][2]
What should patients tell their doctor before starting or while taking Jakafi?
Patients should tell their clinicians about current infections, past infections (including tuberculosis or hepatitis risk factors), other medications, and any history of low blood counts or bleeding. While on Jakafi, they should report fever, unusual bruising or bleeding, worsening weakness, or other new symptoms promptly.[1][2]
When should treatment be paused or adjusted?
Dose adjustments and interruptions are commonly used when blood counts fall or when significant side effects occur, especially anemia, thrombocytopenia, or serious infections. Decisions depend on lab results and clinical status.[1][2]
---
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/
[2] https://www.fda.gov/